Kymera Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Cash & Equivalents	144.09	357.01	120.26	109.97	68.4	47.98
Short-Term Investments	506.84	491.27	368.49	264.92	338.77	394.44
Cash & Short-Term Investments	650.93	848.28	488.74	374.88	407.17	442.42
Cash Growth	40.54%	73.56%	30.37%	-7.93%	-7.97%	49.36%
Accounts Receivable	-	-	-	15	-	-
Other Receivables	-	-	-	3.76	2.54	0.14
Total Trade Receivables	-	-	-	18.76	2.54	0.14
Other Current Assets	26.5	22.94	21.52	11.67	9.71	8.72
Total Current Assets	677.43	871.21	510.27	405.32	419.42	451.27
Net Property, Plant & Equipment	83.35	85.53	97.86	101.08	22.24	21.31
Long-Term Investments	894.72	771.16	362.16	61.43	152.33	125.19
Other Long-Term Assets	13.51	14.91	7.74	7.93	9.15	8.14
Total Assets	1,669	1,743	978.04	575.76	603.13	605.91
Accounts Payable	12.84	4.02	5.99	7.08	4.34	4.01
Accrued Expenses	35.1	42.27	34.87	33.86	27.5	22.97
Current Portion of Leases	13.73	13.76	13.11	6.35	3.94	3.6
Unearned Revenue	-	22.93	13.58	37.88	35.26	61.74
Other Current Liabilities	0.98	0.24	0.22	0.52	0.3	0.23
Total Current Liabilities	62.64	83.21	67.77	85.69	71.34	92.54
Long-Term Leases	66.74	68.5	74.65	78.33	13.39	14.36
Other Long-Term Liabilities	-	11.44	-	16.77	28.25	39.36
Total Long-Term Liabilities	66.74	79.94	74.65	95.1	41.64	53.73
Total Liabilities	129.38	163.15	142.42	180.79	112.98	146.27
Common Stock	0.01	0.01	0.01	0.01	0.01	0.01
Additional Paid-in Capital	2,679	2,644	1,592	926.27	878.88	689.28
Accumulated Other Comprehensive Income	-4.19	1.8	-1.49	-0.55	-4.95	-0.66
Retained Earnings	-1,135	-1,066	-754.61	-530.75	-383.79	-228.98
Shareholders' Equity	1,540	1,580	835.62	394.97	490.15	459.64
Total Liabilities & Equity	1,669	1,743	978.04	575.76	603.13	605.91
Total Debt	80.47	82.25	87.76	84.67	17.34	17.96
Net Cash (Debt)	570.46	766.02	400.98	290.21	389.83	424.46
Net Cash Growth	-25.53%	91.04%	38.17%	-25.56%	-8.16%	52.57%
Net Cash Per Share	6.42	9.07	5.34	4.97	7.23	8.85
Book Value	1,540	1,580	835.62	394.97	490.15	459.64
Book Value Per Share	17.34	18.70	11.14	6.77	9.09	9.58
Tangible Book Value	1,540	1,580	835.62	394.97	490.15	459.64
Tangible Book Value Per Share	17.34	18.70	11.14	6.77	9.09	9.58

Updated Apr 30, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q